Evidence map›Paper›PMID 37893058›Full record

ArticleBiomedicines2023

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.

Christopher D Sarsons, Dean Gilham, Laura M Tsujikawa, Sylwia Wasiak, Li Fu, Brooke D Rakai, Stephanie C Stotz, Agostina Carestia, Michael Sweeney, Ewelina Kulikowski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Christopher D SarsonsResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Dean GilhamResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.ORCID 0000-0002-3194-0324
Laura M TsujikawaResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Sylwia WasiakResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Li FuResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Brooke D RakaiResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Stephanie C StotzResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Agostina CarestiaResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Michael SweeneyResverlogix Corp., 535 Mission St., 14th Floor, San Francisco, CA 94105, USA.
Ewelina KulikowskiResverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.ORCID 0000-0001-5428-3008
Resverlogix (Canada) · CA

Funding

Resverlogix (Canada) N/A
6 · The paper itself

Abstract

Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream activation of pro-apoptotic transcriptional programs. Inhibitors of

Indexed as

apabetaloneBET inhibitorbromodomain and extra-terminal domainDUX4epigeneticsfacioscapulohumeral muscular dystrophyFSHDRNAtranscriptome

Identifiers

PMID37893058
PMCPMC10604783
OpenAlexW4387264455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.